127 related articles for article (PubMed ID: 35181615)
1. Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.
Brown RE; Zhang S; Wang XI
Ann Clin Lab Sci; 2022 Jan; 52(1):27-32. PubMed ID: 35181615
[TBL] [Abstract][Full Text] [Related]
2. Morphoproteomics and Biomedical Analytics Identify the c-Myc, EZH2, Sirt1 and CXCR4 Pathways as Potential Blocks to Differentiation Leading to Proliferation and Metastatic Potential in Sinonasal Undifferentiated Carcinoma (SNUC) and Provide Therapeutic Options: A Case Study.
Brown RE; Roy S; McGuire MF
Ann Clin Lab Sci; 2018 Sep; 48(5):659-664. PubMed ID: 30373873
[TBL] [Abstract][Full Text] [Related]
3. Morphoproteomics Identifies SIRT1 and EZH2 Pathways as Commonalities in B-cell Acute Lymphoblastic Leukemia: Pathogenetic Implications and Opportunities for Therapeutic Intervention.
Brown RE; Konopka KE; Weerasinghe P; Jaitly V; Dasgupta A; McGuire MF; Nguyen ND
Ann Clin Lab Sci; 2017 Jan; 47(1):3-9. PubMed ID: 28249909
[TBL] [Abstract][Full Text] [Related]
4. Morphoproteomics Identifies the EZH2 and SIRT1 Pathways as Potential Blocks to Differentiation in Yolk Sac Tumor of the Ovary and Provides Therapeutic Options: a Case Study.
Kojima YA; Assylbekova B; Zhao B; Nugent E; Brown RE
Ann Clin Lab Sci; 2017 Jan; 47(1):88-91. PubMed ID: 28249923
[TBL] [Abstract][Full Text] [Related]
5. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
6. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
Zhang YA; Yang X; Yao J; Ren Y; Liu P
Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
[TBL] [Abstract][Full Text] [Related]
7. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.
Ma H; Luo X; Zhou P; He N; Zhou J; Liu M; Xie W
J Clin Lab Anal; 2021 Mar; 35(3):e23693. PubMed ID: 33389794
[TBL] [Abstract][Full Text] [Related]
8. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
9. NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates.
Sun H; McGuire MF; Zhang S; Brown RE
Ann Clin Lab Sci; 2015; 45(6):692-701. PubMed ID: 26663801
[TBL] [Abstract][Full Text] [Related]
10. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.
Bisserier M; Wajapeyee N
Blood; 2018 May; 131(19):2125-2137. PubMed ID: 29572378
[TBL] [Abstract][Full Text] [Related]
12. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Scholze H; Stephenson RE; Reynolds R; Shah S; Puri R; Butler SD; Trujillo-Alonso V; Teater MR; van Besien H; Gibbs-Curtis D; Ueno H; Parvin S; Letai A; Mathew S; Singh A; Cesarman E; Melnick A; Giulino-Roth L
Blood Adv; 2020 Oct; 4(20):5226-5231. PubMed ID: 33104794
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
14. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
16. Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.
Duncan VE; Ping Z; Varambally S; Peker D
Leuk Lymphoma; 2017 Jan; 58(1):179-184. PubMed ID: 27184221
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
[TBL] [Abstract][Full Text] [Related]
18. Carnosol-mediated Sirtuin 1 activation inhibits Enhancer of Zeste Homolog 2 to attenuate liver fibrosis.
Zhao H; Wang Z; Tang F; Zhao Y; Feng D; Li Y; Hu Y; Wang C; Zhou J; Tian X; Yao J
Pharmacol Res; 2018 Feb; 128():327-337. PubMed ID: 29106960
[TBL] [Abstract][Full Text] [Related]
19. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.
Johnson DP; Spitz GS; Tharkar S; Quayle SN; Shearstone JR; Jones S; McDowell ME; Wellman H; Tyler JK; Cairns BR; Chandrasekharan MB; Bhaskara S
Oncotarget; 2015 Mar; 6(7):4863-87. PubMed ID: 25605023
[TBL] [Abstract][Full Text] [Related]
20. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]